132 related articles for article (PubMed ID: 18202797)
1. Metastatic renal cancer and patient survival as a criterion of treatment response.
Stathopoulos GP; Koutantos J; Rigatos SK; Stathopoulos J; Batzios S; Batziou C
Oncol Rep; 2008 Feb; 19(2):477-81. PubMed ID: 18202797
[TBL] [Abstract][Full Text] [Related]
2. Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience.
Marx G; Taylor J; Goldstein D
Intern Med J; 2005 Jan; 35(1):34-8. PubMed ID: 15667466
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience.
O'Brien MF; Rea D; Rogers E; Bredin H; Butler M; Grainger R; McDermott TE; Mullins G; O'Brien A; Twomey A; Thornhill J
Eur Urol; 2004 May; 45(5):613-8; discussion 619. PubMed ID: 15082204
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous administration of interferon alpha and gamma in patients with metastatic renal cell carcinoma.
Koga S; Nishikido M; Matsuya F; Kanetake H; Saito Y
Anticancer Res; 1999; 19(6C):5547-50. PubMed ID: 10697614
[TBL] [Abstract][Full Text] [Related]
6. Multi-cytokine therapy for advanced renal cell carcinoma: determination of the minimal effective dose.
Hamada I; Kato M; Okada K
Anticancer Res; 2002; 22(4):2429-36. PubMed ID: 12174939
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.
Culine S; Iborra F; Mottet N; Avancès C; de Graeve B; Volpé P; Vignoud J; Bringer JP; Marroncle M; Le Pellec L; Ayuso D; Jansen E; Faix A; Rebillard X
Am J Clin Oncol; 2006 Apr; 29(2):148-52. PubMed ID: 16601433
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma.
Obara W; Mizutani Y; Oyama C; Akaza H; Ishii N; Kohri K; Namiki M; Okuyama A; Shima H; Yokoyama M; Shuin T; Miki T; Watanabe Y; Fujioka T
Int J Urol; 2008 Sep; 15(9):794-9. PubMed ID: 18651865
[TBL] [Abstract][Full Text] [Related]
9. A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma.
Huland E; Heinzer H; Huland H
Folia Biol (Praha); 2000; 46(6):241-50. PubMed ID: 11140857
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide therapy for metastatic renal cell carcinoma.
Amato RJ; Hernandez-McClain J; Saxena S; Khan M
Am J Clin Oncol; 2008 Jun; 31(3):244-9. PubMed ID: 18525302
[TBL] [Abstract][Full Text] [Related]
11. Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery.
Samlowski WE; Majer M; Boucher KM; Shrieve AF; Dechet C; Jensen RL; Shrieve DC
Cancer; 2008 Nov; 113(9):2539-48. PubMed ID: 18780316
[TBL] [Abstract][Full Text] [Related]
12. Cytokine therapy for metastatic renal cell carcinoma.
Bukowski RM
Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
[TBL] [Abstract][Full Text] [Related]
13. Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients.
Sartore-Bianchi A; Soriani A; Mattioni R; Vaglio A; Buzio C; Porta C
Oncol Rep; 2004 Oct; 12(4):855-9. PubMed ID: 15375512
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
Amato RJ; Malya R; Rawat A
Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
[TBL] [Abstract][Full Text] [Related]
15. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
Négrier S; Perol D; Ravaud A; Bay JO; Oudard S; Chabaud S; Fargeot P; Delva R; Deplanque G; Gravis G; Escudier B;
Clin Cancer Res; 2008 Sep; 14(18):5907-12. PubMed ID: 18794104
[TBL] [Abstract][Full Text] [Related]
16. [High-dose medroxyprogesterone acetate in the treatment of metastatic carcinoma of renal parenchyma].
Popov I; Jelić S; Milanović N; Kovcin V; Vuletić Lj
Srp Arh Celok Lek; 1996; 124(3-4):73-6. PubMed ID: 9102823
[TBL] [Abstract][Full Text] [Related]
17. Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2).
Huland E; Heinzer H; Huland H
Anticancer Res; 1999; 19(4A):2679-83. PubMed ID: 10470219
[TBL] [Abstract][Full Text] [Related]
18. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.
Lee CP; Patel PM; Selby PJ; Hancock BW; Mak I; Pyle L; James MG; Beirne DA; Steeds S; A'Hern R; Gore ME; Eisen T
J Clin Oncol; 2006 Feb; 24(6):898-903. PubMed ID: 16484699
[TBL] [Abstract][Full Text] [Related]
20. Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma.
Hosokawa Y; Kishino T; Ono T; Oyama N; Hayashi K; Momose H
Int J Urol; 2004 Oct; 11(10):906-8. PubMed ID: 15479299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
